Karol

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4794551/publications.pdf

Version: 2024-02-01

		304602	330025
61	1,527	22	37
papers	citations	h-index	g-index
63	63	63	2978
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Longâ€term firstâ€inâ€man Phase I/II study of an adjuvant dendritic cell vaccine in patients with highâ€risk prostate cancer after radical prostatectomy. Prostate, 2022, 82, 245-253.	1.2	13
2	Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. European Urology, 2022, 81, 431.	0.9	1
3	Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCl Insight, 2022, 7, .	2.3	6
4	Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity. Cancer Gene Therapy, 2022, 29, 1276-1284.	2.2	3
5	Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis. Marine Drugs, 2022, 20, 228.	2.2	3
6	<i>In situ</i> expression of <scp>ERG</scp> protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis. Molecular Oncology, 2022, 16, 2810-2822.	2.1	3
7	A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease. Scandinavian Journal of Urology, 2022, 56, 274-276.	0.6	O
8	The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism. International Urology and Nephrology, 2021, 53, 691-698.	0.6	4
9	High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity. Neoplasia, 2021, 23, 634-641.	2.3	16
10	Vitamin D and Vitamin Dâ€binding protein and risk of bladder cancer: A nested caseâ€control study in the Norwegian Janus Serum Bank Cohort. Cancer Medicine, 2021, 10, 4107-4116.	1.3	4
11	Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort. Clinical Epidemiology, 2021, Volume 13, 801-811.	1.5	3
12	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	5.1	48
13	Prediagnostic Serum-25 Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: Answer to a Short Comment [Response to Letter]. Clinical Epidemiology, 2021, Volume 13, 1061-1062.	1.5	O
14	Lifestyle associated factors and risk of urinary bladder cancer: A prospective cohort study from Norway. Cancer Medicine, 2020, 9, 4420-4432.	1.3	7
15	A cross-sectional study of current work ability after radical prostatectomy. BMC Urology, 2020, 20, 9.	0.6	4
16	Biochemical relapse in very high-risk prostate cancer after radical prostatectomy and DC-vaccine loaded with tumor RNA, hTERT, and survivin Journal of Clinical Oncology, 2020, 38, 324-324.	0.8	1
17	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842.	0.9	148
18	Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer. Scientific Reports, 2019, 9, 13579.	1.6	38

#	Article	IF	CITATIONS
19	Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. European Urology, 2019, 75, 498-505.	0.9	108
20	Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study. BMJ Open, 2018, 8, e019309.	0.8	9
21	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276.	2.9	12
22	Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 2018, 78, 186-192.	1.2	11
23	Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Populationâ€Based Study. Prostate, 2017, 77, 859-865.	1.2	32
24	Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. Urology, 2017, 110, 140-147.	0.5	8
25	Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA. Clinical Nutrition, 2017, 36, 672-679.	2.3	65
26	Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations. BMC Urology, 2017, 17, 111.	0.6	16
27	The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort. Prostate, 2016, 76, 207-214.	1.2	21
28	Addressing erectile dysfunction in prostate cancer survivors after radical prostatectomy. Expert Review of Quality of Life in Cancer Care, 2016, 1, 403-420.	0.6	2
29	Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality. Prostate, 2016, 76, 1088-1094.	1.2	15
30	Penile cancer in Scandinavia: Current practice and future perspectives. Scandinavian Journal of Urology, 2016, 50, 90-92.	0.6	10
31	Ability to Reach Orgasm in Patients With Prostate Cancer Treated With Robot-assisted Laparoscopic Prostatectomy. Urology, 2016, 92, 38-43.	0.5	8
32	MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features. Oncotarget, 2016, 7, 40297-40313.	0.8	34
33	The prognostic value of reactive stroma on prostate needle biopsy: A populationâ€based study. Prostate, 2015, 75, 662-671.	1.2	29
34	Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: A single-centre experience. Scandinavian Journal of Urology, 2015, 49, 218-223.	0.6	2
35	A comparative study of erectile function and use of erectile aids in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy. Scandinavian Journal of Urology, 2015, 49, 433-439.	0.6	9
36	The Length of a Positive Surgical Margin Is of Prognostic Significance in Patients with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy. Urologia Internationalis, 2014, 93, 289-295.	0.6	18

#	Article	IF	CITATIONS
37	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	0.9	195
38	Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance. European Radiology, 2013, 23, 1158-1166.	2.3	21
39	Robot-assisted radical prostatectomy of clinical high-risk patients with prostate cancer: A controlled study of operative and short-term postoperative events. Scandinavian Journal of Urology, 2013, 47, 449-455.	0.6	10
40	Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? - Findings from a prospective national study. Scandinavian Journal of Urology, 2013, 47, 92-100.	0.6	25
41	Bother problems in prostate cancer patients after curative treatment. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1067-1078.	0.8	22
42	Blocking mtDNA Replication Upregulates the Expression of Stemness-related Genes in Prostate Cancer Cell Lines. Ultrastructural Pathology, 2013, 37, 258-266.	0.4	4
43	SHBG Is an Important Factor in Stemness Induction of Cells by DHT In Vitro and Associated with Poor Clinical Features of Prostate Carcinomas. PLoS ONE, 2013, 8, e70558.	1.1	8
44	Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumor Biology, 2012, 33, 967-978.	0.8	28
45	Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. Prostate, 2012, 72, 668-676.	1.2	7
46	Robot-assisted laparoscopic prostatectomy in a 68-year-old patient with previous heart transplantation and pelvic irradiation. Journal of Robotic Surgery, 2012, 6, 81-83.	1.0	6
47	Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immuneâ€evasive B7â€H3â€expressing cell population?. International Journal of Urology, 2012, 19, 749-756.	0.5	25
48	Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer. BJU International, 2012, 109, 1489-1494.	1.3	28
49	Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother. BJU International, 2012, 109, 1366-1374.	1.3	39
50	Transperineal prostate biopsy detects significant cancer in patients with elevated prostateâ€specific antigen (PSA) levels and previous negative transrectal biopsies. BJU International, 2012, 110, E69-75.	1.3	58
51	Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU International, 2012, 110, 1721-1728.	1.3	81
52	Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center. Acta Oncol \tilde{A}^3 gica, 2011, 50, 408-414.	0.8	7
53	Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties. PLoS ONE, 2011, 6, e29170.	1.1	88
54	Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry. BJU International, 2010, 105, 805-811.	1.3	35

#	Article	IF	CITATION:
55	Do Perceptions of Adverse Events Differ Between Patients and Physicians? Findings From a Randomized, Controlled Trial of Radical Treatment for Prostate Cancer. Journal of Urology, 2010, 184, 525-531.	0.2	15
56	Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate. Acta Oncol \tilde{A}^3 gica, 2007, 46, 1195-1197.	0.8	16
57	Photodynamic therapy with methyl aminolevulinate for atypia/carcinoma in situ of the penis. Scandinavian Journal of Urology and Nephrology, 2007, 41, 507-510.	1.4	24
58	Sentinel node procedure in low-stage/low-grade penile carcinomas. Scandinavian Journal of Urology and Nephrology, 2006, 40, 204-207.	1.4	13
59	Uptake and intracellular transportation of a bacterial surface protein in lymphoid cells. Molecular Microbiology, 2002, 44, 917-934.	1.2	4
60	Regulation of Transcriptional Activity of the Murine CD40 Ligand Promoter in Response to Signals Through TCR and the Costimulatory Molecules CD28 and CD2. Journal of Immunology, 2001, 166, 4578-4585.	0.4	32
61	Regulation of B cell growth and differentiation via CD21 and CD40. European Journal of Immunology, 1996, 26, 2203-2207.	1.6	23